Abstracts tagged "Clinical research methods"

Abstract Number: 2919 • 2013 ACR/ARHP Annual Meeting
The Clinical Utility Of Flow-Mediated Dilation In Systemic Sclerosis
Tracy M. Frech¹, Ashley Walker², Zachary Barrett-Okeefe², Russell Richardson², D. Walter Wray² and Anthony Donato², ¹Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, ²University of Utah, Salt Lake, UT
Background/Purpose: In systemic sclerosis (SSc, scleroderma) vasculopathy can result in the end-stage manifestation of a digital ulcer (DU). We hypothesized that bedside flow mediated dilatation…
Abstract Number: 1109 • 2013 ACR/ARHP Annual Meeting
Which Baseline Characteristics Influence The Response To Milnacipran In Patient With Fibromyalgia ?
Olivier Vitton¹, Olivier Vitton¹, Pierre Bunouf², Lilia Abtroun³ and Frederic Bonfils¹, ¹Pierre Fabre, Castres, France, ²Pierre Fabre, Toulouse, France, ³Ariana Pharma, Paris, France
Background/Purpose: Milnacipran (MLN) has demonstrated its benefit in treating patients with fibromyalgia. Fibromyalgia is a persistent pain condition that aggregates numerous symptoms (pain, fatigue, sleep…
Abstract Number: 1847 • 2012 ACR/ARHP Annual Meeting
Status of the Rheumatology Clinical Trials Portfolio: Data From Clinicaltrials.Gov
Ankoor Shah¹, Samuel Broderick², Karen Chiswell², Asba Tasneem² and John S. Sundy², ¹Rheumatology and Immunology, Duke University Medical Center, Durham, NC, ²Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background/Purpose: In an effort to provide a comprehensive listing of clinical trials Congress initiated the creation of the ClinicalTrials.gov (CT.gov) registry in 1997. In 2007…
Abstract Number: 121 • 2012 ACR/ARHP Annual Meeting
The Diagnostic Value of Color Doppler Ultrasonography in Giant Cell Arteritis
Merete L. Hetland¹, Geirmund Myklebust², Glenn Haugeberg³ and Andreas P. Diamantopoulos⁴, ¹Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ²Rheumatology, Hospital of Southern Norway HF, Kristiansand, Norway, ³Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁴Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway
Background/Purpose: Color Doppler Ultrasonography (CDUS) has been shown to be a non-invasive promising tool to diagnose Giant Cell Arteritis (GCA). The aim of our study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].